

<p style="text-align: center;"><b>O I P E</b> <b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)</p> <p style="text-align: center;"><i>OCT 14 2001 MAIL DATE CANCELLED</i></p>					ATTY. DOCKET NO.	APPLICATION NO.				
					10167-004	09/533,399				
					APPLICANT					
					Santoro et al.					
<table border="1"> <tr> <td>FILING DATE</td> <td>GROUP</td> </tr> <tr> <td>March 22, 2000</td> <td>1617</td> </tr> </table>					FILING DATE	GROUP	March 22, 2000	1617		
FILING DATE	GROUP									
March 22, 2000	1617									
<b>U.S. PATENT DOCUMENTS</b>										
EXAMINER- INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
✓	CU 5,116,869	5/26/92	Sugiura et al.	574	956					
✓	CV 5,216,183	6/1/93	Sugiura et al.	574	586					
✓	CW 6,087,401	7/11/00	Koyama et al.	574	680					
✓	CX 6,111,145	8/29/00	Kobayashi	568	878					
✓	CY 6,136,854	10/24/00	Koyama et al.	574	532					
<b>FOREIGN PATENT DOCUMENTS</b>										
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
						YES	NO			
✓	CZ EP 0 106 575	4/25/84	EU							
✓	DA EP 0 180 399	5/7/86	EU							
✓	DB EP 0 701 988	3/20/96	EU							
✓	DC EP 0 894 435	2/3/99	EU (in French with English Abstract)							
✓	DD EP 1 048 641	11/2/00	EU							
✓	DE JP 09 169780	6/30/97	JP (in Japanese with English Abstract)							
✓	DF JP 07 233143	9/5/95	JP (in Japanese with English Abstract)							
✓	DG JP 62 000044	1/6/87	JP (in Japanese with English Abstract)							
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>										
✓	DH	Myers et al. 1996, "An improved preparation of highly enantiomerically enriched (R)-(+)-4-tert-butylidimethylsiloxy-2-cyclopenten-1-one". TETRAHEDRON LETT. 37(18):3083-86								
✓	DI	Tanaka et al., 1986, "Antiherpetic action of prostaglandin D <sub>2</sub> ", Prostaglandines Lewkotrienes and Medicine 25: 131-138								
EXAMINER <i>AS</i>			DATE CONSIDERED <i>3/20/02</i>							

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.